Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023 - Seite 2

Dr. Tumlin continued, “There remains a significant unmet need for well-tolerated, convenient, and efficacious therapies in autoimmune kidney diseases, and dual BAFF/APRIL inhibition has the potential to be an important disease-modifying mechanism, especially if considered early in the treatment paradigm.”

“Even at this low 80 mg dose level of povetacicept, the improvements in proteinuria, accompanied by analogous changes in Gd-IgA1, are impressive and support its potential to be an important therapy for IgAN,” remarked Jonathan Barratt, PhD, FRCP, Mayer Professor of Renal Medicine at the University of Leicester. “Based on this data, advancement of povetacicept to a pivotal trial in IgA nephropathy, where it has already accumulated a reasonably sized clinical experience, seems urgently warranted. The initial findings in primary membranous nephropathy, a disease with no approved therapies, are equally encouraging. Further study is clearly warranted and confirmation of the results in additional pMN patients, along with correlation with renal outcomes, may facilitate a rapid development path.”

“These results are the first of what will hopefully be several data readouts over the next 12-18 months that will help validate the potential activity of povetacicept across multiple autoimmune diseases,” noted Stanford Peng, MD, PhD, President and Head of Research and Development at Alpine. “We eagerly await the initial data from the next 240 mg dose level in the first half of 2024. In the meantime, these data support our plan to advance povetacicept rapidly to a pivotal trial in IgAN, pending regulatory agreement, in the second half of next year. In addition, we plan to initiate RUBY-2, a phase 2 study of povetacicept in systemic lupus erythematosus.”

American Society of Nephrology – Kidney Week 2023

Date/Time: Thursday, November 2, 2023, 10:00am – 12:00pm ET
Poster Title: Povetacicept, an Enhanced Dual BAFF/APRIL Antagonist, in Autoantibody-Associated Glomerulonephritis (GN)
Poster Board Number: TH-PO1125
Session Name: Late-Breaking Posters
Location: Exhibit Hall, Pennsylvania Convention Center, Philadelphia
Presenter: James Tumlin, M.D., Professor of Medicine at Emory University School of Medicine, Founder and Chief Executive Officer of NephroNet Clinical Trials Consortium

Investor Conference Call and Webcast Information

Date/Time: Thursday, November 2, 2023, at 4:30 pm – 5:30 pm ET

Alpine will host a conference call and webcast to discuss the data update from ASN as well as provide a corporate update. Members of the Alpine executive team will be joined by James Tumlin, M.D., Professor of Medicine at Emory University School of Medicine, Founder and Chief Executive Officer of NephroNet Clinical Trials Consortium, and Jonathan Barratt, Ph.D., FRCP, the Mayer Professor of Renal Medicine at the University of Leicester.